Skip to main content
SpringerLink
Log in

Late Effects of Langerhans Cell Histiocytosis and the Association of LCH with Malignancy

  • Chapter
  • First Online:
Histiocytic Disorders

  • 1342 Accesses

Abstract

The term permanent consequences is often used to describe the portfolio of possible late complications occurring in patients with LCH. Consequences may be already evident at the moment of LCH diagnosis or become manifest even more than 10 years after the end of therapy. They may be due either to the site of the original disease or to age at treatment and type and doses of treatments received.

Since the bony skeleton is the most common site of involvement of LCH, the commonest sequelae tend to be orthopaedic and include pathological fractures, malformation, scoliosis and vertebra plana.

Diabetes insipidus is the most reported endocrine abnormality, and patients with multisystem disease and involvement of the craniofacial bones are those at higher risk. Other abnormalities may affect anterior pituitary with growth hormone deficit being the most frequent.

Neurological problems such as cerebellar ataxia, psychological problems and learning difficulties can occur, with impact on school performance and quality of life. Hearing loss and pulmonary problems are other common possible late complications. Possible other side effects should also be carefully monitored in patients treated with novel targeted therapies involving BRAF/MAPK pathways. LCH may be associated with other malignancies occurring either before, concurrently or after LCH diagnosis. In general ALL usually precedes LCH, while AnLL and solid tumours develop after LCH. Long-term and patient-oriented follow-up in children with LCH is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Komp DM, El Mahdi A, Starling KA, Easley J, Vietti TJ, Berry DH, George SL. Quality of survival in histiocytosis X: a southwest oncology group study. Med Pediatr Oncol. 1980;8:35–40.

    Article  CAS  PubMed  Google Scholar 

  2. Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol. 1981;3:165–8.

    Article  Google Scholar 

  3. Sims DG. Histiocytosis X. Follow-up of 43 cases. Arch Dis Child. 1977;52:433–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ceci A, Terlizzi MD, Colella R, Loiacono G, Balducci D, Surico G, Castello M, Testi AM, Bernardi B, Indolfi P, Macchia P, Madon E, Mancini A, Rosati D. Langerhans cell histiocytosis in childhood: results from the Italian cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993;21:259–64.

    Article  CAS  PubMed  Google Scholar 

  5. Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:72–80.

    Article  CAS  PubMed  Google Scholar 

  6. Donadieu J, French LCH Study group. A multi-centre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75:17–24.

    Article  Google Scholar 

  7. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, san Francisco. J Clin Oncol. 1996;14:2073–82.

    Article  CAS  PubMed  Google Scholar 

  8. Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, Rey G, McClain KL, Janka-Schaub G, Egeler M. Permanent consequences in Langerhans cell histiocytosis patients. A pilot study from the histiocyte society – late effects study group. Pediatr Blood Cancer. 2004;42:438–44.

    Article  PubMed  Google Scholar 

  9. Chellapandian D, Shaikh F, van den Bos C, Somers GR, Astigarraga I, Jubran R, Degar B, Carret AS, Mandel K, Belletrutti M, Dix D, Visser J, Abuhadra N, Chang T, Rollins B, Whitlock J, Weitzman S, Abla O. Management and outcome of patients with Langerhans cell Histiocytosis and single-bone CNS-risk lesions: a multi-institutional retrospective study. Pediatr Blood Cancer. 2015;62:2162–6.

    Article  PubMed  Google Scholar 

  10. Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J, Aladjidi N, Plat G, Jeziorski E, Galambrun C, Mansuy L, Lutz P, Deville A, Armari-Alla C, Reguerre Y, Fraitag S, Coulomb A, Gandemer V, Leboulanger N, Moshous D, Hoang-Xuan K, Tazi A, Heritier S, Emile JF, Donadieu J. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174:887–98.

    Article  CAS  PubMed  Google Scholar 

  11. Kim BE, Koh KN, Suh JK, Im HJ, Song JS, Lee JW, et al. Clinical features and treatment outcomes of Langerhans cell Histiocytosis: a Nationwide survey from Korea Histiocytosis working party. J Pediatr Hematol Oncol. 2014;36:125–33.

    Article  PubMed  Google Scholar 

  12. Lau LM, Stuurman K, Weitzman S. Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. Pediatr Blood Cancer. 2008;50:607–12. Lau; Skeletal Langerhans Cell Histiocytosis in Children: Permanent Consequences

    Article  PubMed  Google Scholar 

  13. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfman B, Gatterer-Meinz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90- study. Med Pediatr Oncol. 2001;37:108–14.

    Article  CAS  PubMed  Google Scholar 

  14. Greenberger JS, Cassady JR, Jaffe N, Vawter G, Crocker AC. Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int J Radiat Oncol Biol Phys. 1979;5:1749–55.

    Article  CAS  PubMed  Google Scholar 

  15. Henry R, Sweeney E. Langerhans cell Histiocytosis: case reports and literature review. Pediatr Dent. 1996;18:11–6.

    CAS  PubMed  Google Scholar 

  16. Braier J, Chantada G, Rosso D, Bernaldez P, Amaral D, Latella A, Balancini B, Masautis A, Goldberg J. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999;16:377–85.

    Article  CAS  PubMed  Google Scholar 

  17. Nanduri VR, Pritchard J, Chong WK, Phelps PD, Sirimanna TS, Bailey CM. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J of Ped Otorhinolaryngology. 1998;46(1–2):109–15.

    Article  CAS  Google Scholar 

  18. Hoeger PH, Diaz C, Malone M, Pritchard J, Harper JI. Juvenile xanthogranuloma as a sequel to Langerhans cell histiocytosis: a report of three cases. Clin Exp Dermatol. 2001;26:391–4.

    Article  CAS  PubMed  Google Scholar 

  19. Hoeger PH, Nanduri VR, Harper JI, Pritchard J. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child. 2000;82:483–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Di Iorgi N, Allegri AE, Napoli F, Calcagno A, Calandra E, Fratangeli N, Vannati M, Rossi A, Bagnasco F, Haupt R, Maghnie M. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99:1264–72.

    Article  PubMed  Google Scholar 

  21. Nanduri VR, Bareille P, Pritchard J, Stanhope R. Growth and endocrine disorders in Langerhans cell histiocytosis. Clin Endo. 2000;53:509–15.

    Article  CAS  Google Scholar 

  22. Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, Pritchard J. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. 1989;321:1157–62.

    Article  CAS  PubMed  Google Scholar 

  23. Dunger DB, Seckl JR, Grant DB, Yeoman E, Lightman SL. A short water deprivation test incorporating urinary arginine vasopressin estimations for the investigation of posterior pituitary function in children. Acta Endocrinol. 1988;117:13–8.

    CAS  PubMed  Google Scholar 

  24. Grois N, Flucher Wolfram B, Heitger A, Mostbeck GH, Hofmann J, Gadner H. Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med Pediatr Oncol. 1995;24:248–56.

    Article  CAS  PubMed  Google Scholar 

  25. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX study group. Klin Pediatr. 2000;212:139–44.

    Article  CAS  Google Scholar 

  26. Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans call histiocytosis: is it reversible? Med Pediatr Oncol. 1997;28:289–93.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenzweig KE, Arceci RJ, Tarbell NJ. Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated. Med Pediatr Oncol. 1997;29:36–40.

    Article  CAS  PubMed  Google Scholar 

  28. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol. 2003;25:575–7. PMID: 23258922

    Article  PubMed  Google Scholar 

  29. Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, Yasui M, Koga Y, Kobayashi R, Ishii E, Fujimoto J, Horibe K, Bessho F, Tsunematsu Y, Imashuku S. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans cell Histiocytosis study group-02 protocol study. Int J Hematol. 2016;104:99–109.

    Article  CAS  PubMed  Google Scholar 

  30. Toro Galván S, Planas Vilaseca A, Michalopoulou Alevras T, Torres Díaz A, Suárez Balaguer J, Villabona AC. Endocrine changes in histiocytosis of the hypothalamic-pituitary axis. Endocrinol Nutr. 2015;62:72–9.

    Article  PubMed  Google Scholar 

  31. Rami B, Schneider U, Wandl-Vergesslich K, Frisch H, Schober E. Primary hypothyroidism, central diabetes insipidus and growth hormone deficiency in multisystem Langerhans cell histiocytosis: a case report. Acta Paediatr. 1998;87:112–4.

    Article  CAS  PubMed  Google Scholar 

  32. Bernstrand C, Cederlund K, Sandstedt B, Ahstrom L, Lundell M, Dahlquist G, Henter JI. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol. 2001;36:459–68.

    Article  CAS  PubMed  Google Scholar 

  33. Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015;14:10–30.

    Google Scholar 

  34. Habib SB, Congleton J, Carr D, Partridge J, Corrin B, Geddes DM, Banner N, Yacoub M, Burke M. Recurrence of recipient Langerhans’ cell histiocytosis following bilateral lung transplantation. Thorax. 1998;53:323–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis. Diagnosis, natural history, management, and outcome. Cancer. 1999;85:2278–90.

    Article  CAS  PubMed  Google Scholar 

  36. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:287–305.

    Article  CAS  PubMed  Google Scholar 

  37. Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, Nanduri V, Prosch H, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156:881.

    Article  Google Scholar 

  38. Whitsett SF, Kneppers K, Coppes MJ, Egeler RM. Neuropsychological deficits in children with Langerhans cell histiocytosis. Med Pediatr Oncol. 1999;33:486–92.

    Article  CAS  PubMed  Google Scholar 

  39. Nanduri VR, Lillywhite L, Chapman C, Parry L, Pritchard J, Vargha-Khadem F. Cognitive outcome of long term survivors of multisystem Langerhans cell histiocytosis: a single-institution, cross-sectional study. J Clin Onc. 2003;21:2961–7.

    Article  Google Scholar 

  40. Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis. Med Pediatr Oncol. 2002;38:178–82.

    Article  PubMed  Google Scholar 

  41. Hadzic N, Pritchard J, Webb D, Portmann B, Heaton ND, Rela M, Dhawan A, Baker AJ, Mieli VG. Recurrence of Langerhans cell histiocytosis in the graft after pediatric liver transplantation. Transplantation. 2000;70:815–9.

    Article  CAS  PubMed  Google Scholar 

  42. Nanduri VR, Pritchard J, Levitt G, Glaser AW. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer. 2006;42(15):2563–9. Nesbit ME, Keiffer S, D’Angio GJ. (1969). Reconstitution of vertebral height in Histiocytosis X: a long-term follow-up. J Bone Joint Surg;51:1360–8.

    Article  PubMed  Google Scholar 

  43. Chiles LR, Christian MM, McCoy DK, Hawkins HK, Yen AH, Raimer SS. Langerhans cell histiocytosis in a child while in remission for acute lymphocytic leukemia. J Am Acad Dermatol. 2001;45:S233–4.

    Article  CAS  PubMed  Google Scholar 

  44. Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME. Acute leukemia in association with Langerhans cell Histiocytosis. Med Pediatr Oncol. 1994;2:381–5.

    Google Scholar 

  45. Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-malignancy study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998;12:369–78.

    Article  CAS  PubMed  Google Scholar 

  46. Haupt R, Fears TR, Heise A, Gadner H, Loiacono G, De Terlizzi M, Tucker MA. Risk of secondary leukemia after treatment with etoposide (VP- 16) for Langerhans' cell histiocytosis in Italian and Austrian- German populations. Int J Cancer. 1997;71:9–13.

    Article  CAS  PubMed  Google Scholar 

  47. Kager L, Heise A, Minkov M, Mobius D, Kotte W, Schulte-Overberg U, Henze G, Gadner H. Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis. Pediatr Hematol Oncol. 1999;16:251–6. Review

    Article  CAS  PubMed  Google Scholar 

  48. Lopes LF, de Camargo B. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH). Med Pediatr Oncol. 1999;32:315.

    Article  CAS  PubMed  Google Scholar 

  49. Macedo Silva ML, Land MG, Maradei S, Otero L, Veith M, Brito G, Klumb C, Fernandez T, Pombo-de-Oliveira MS. Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis. Cancer Genet Cytogenet. 2002;135:101–2.

    Article  Google Scholar 

  50. Raj A, Bendon R, Moriarty T, Suarez C, Bertolone S. Langerhans cell histiocytosis following childhood acute lymphoblastic leukemia. Am J Hematol. 2001;68:284–6.

    Article  CAS  PubMed  Google Scholar 

  51. Wu JH, Lu MY, Lin KH, Jou ST, Lin DT. Development of acute lymphoblastic leukemia in a child after treatment of Langerhans cell histiocytosis: report of one case. Acta Paediatr Taiwan. 1999;40:441–2.

    CAS  PubMed  Google Scholar 

  52. Ghosn M, Haddad A, Nassar M, Abadjjian G, El Karak F, Aftimos P. Acute myeloid leukemia and Langerhans cell Histiocytosis: multiple theories for an unusual presentataion. Leukemia Res. 2009;34:406–8. doi:10.1016/jleukres.2009.07.025.

    Article  Google Scholar 

  53. Greaves W, Bueso-Ramos C, Fayad L. Classical Hodgkin lymphoma associated with Langerhans cell Histiocytosis: Multiagent chemotherapy resulted in Histologic resolution of both classical Hodgkin lymphoma and Langerhans cell proliferation components. JCO. 2011;29(4):e76–8. doi:10.1200/JCO.2010.31.2413.

    Article  Google Scholar 

  54. Vassallo R, Ryu J, Schroeder D, Decker P, Limper A. Clinical outcomes of pulmonary Langerhans cell Histiocytosis in adults. N Engl J Med. 2002;346:484–90.

    Article  PubMed  Google Scholar 

  55. Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE. Clinicopathologic features of histiocytic lesions following ALL, with review of the literature. Pediatr Dev Pathol. 2010;13:225–37.

    Article  PubMed  Google Scholar 

  56. Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition. Hematology Am Soc Hematol Educ Program. 2015;2015:565–70. doi:10.1182/asheducation-2015.1.565.

    PubMed  Google Scholar 

  57. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis, blood. 2010. Sep 16. 2010;116(11):1919–23.

    CAS  Google Scholar 

  58. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909–20. doi:10.1158/1535-7163.MCT-11-0989. Epub 2012 Mar 2

    Article  CAS  PubMed  Google Scholar 

  59. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500. doi:10.1182/blood-2012-07-446286.

    Article  CAS  PubMed  Google Scholar 

  60. Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014;15(5):589–92. doi:10.1517/14656566.2014.881471. Epub 2014 Jan 24

    Article  CAS  PubMed  Google Scholar 

  61. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30:316–21.

    Article  CAS  PubMed  Google Scholar 

  62. Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–9. doi:10.1001/jamadermatol.2015.1745.

    Article  PubMed  Google Scholar 

  63. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–72. doi:10.1038/nature09627. Epub 2010 Nov 24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–30. doi:10.1038/nature08902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Grey A, Cooper A, McNeil C, O'Toole S, Thompson J, Grimison P. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Intern Med J. 2014;44(6):597–600. doi:10.1111/imj.12415.

    Article  CAS  PubMed  Google Scholar 

  67. Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors Vemurafenib and Dabrafenib. JAMA Oncol. 2015;1(8):1133–4. doi:10.1001/jamaoncol.2015.1713.

    Article  PubMed  Google Scholar 

  68. US Food and Drug Administration. Tefinlar Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf Last revised May 2013.

  69. Bronte E, Bronte G, Novo G, Bronte F, Bavetta MG, Lo RG. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6(34):35589–601. doi:10.18632/oncotarget.5853.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Modak S, Asante-Korang A, Steinherz LJ, Grana N. Trametinib-induced left ventricular dysfunction in a child with relapsed Neuroblastoma. J Pediatr Hematol Oncol. 2015;37(6):e381–3. doi:10.1097/MPH.0000000000000364.

    Article  PubMed  Google Scholar 

  71. Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25(7):1437–41. doi:10.1093/annonc/mdu169. Epub 2014 May 26

    Article  CAS  PubMed  Google Scholar 

  72. Niro A, Strippoli S, Alessio G, Sborgia L, Recchimurzo N, Guida M. Ocular toxicity in metastatic melanoma patients treated with Mitogen-activated protein Kinase Kinase inhibitors: a case series. Am J Ophthalmol. 2015;160(5):959–67. doi:10.1016/j.ajo.2015.07.035. e1. Epub 2015 Jul 29

    Article  CAS  PubMed  Google Scholar 

  73. LCH-IV International Collaborative Treatment Protocol for Langerhans Cell Histiocytosis. https://clinicaltrials.gov/ct2/show/NCT02205762

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, Watford General Hospital, Watford, WD18 0HB, UK

    Vasanta Nanduri MD, MRCP, FRCPCH

  2. After Cancer Treatment Survivorship Program, Children’s Hospital of Orange County, 1201 W. La Veta, Orange, CA, 92868, USA

    Lilibeth R. Torno MD

  3. Epidemiology and Biostatistics Unit, Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy

    Riccardo Haupt MD

Authors
  1. Vasanta Nanduri MD, MRCP, FRCPCH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lilibeth R. Torno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Haupt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Haupt MD .

Editor information

Editors and Affiliations

  1. University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada

    Oussama Abla

  2. Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany

    Gritta Janka

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nanduri, V., Torno, L.R., Haupt, R. (2018). Late Effects of Langerhans Cell Histiocytosis and the Association of LCH with Malignancy. In: Abla, O., Janka, G. (eds) Histiocytic Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-59632-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59632-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59631-0

  • Online ISBN: 978-3-319-59632-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation